Tauns Laboratories, Inc. (197A) AI Stock Analysis

• Market Cap: ¥57.59B
• Dividend Yield: 4.84%
• Average Volume (3M): 400.80K
• Price to Earnings (P/E): 8.9
• Beta (1Y): 0.46
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 271
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Specialties
• EPS (TTM): -3.46
• Shares Outstanding: 103,199,776
• 10 Day Avg. Volume: 355,040
• 30 Day Avg. Volume: 400,796
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: ¥627.00 ▲(12.97% Upside)

Tauns Laboratories, Inc. scores well due to its strong financial performance and attractive valuation. The company's consistent revenue growth and profitability are significant strengths, although rising debt levels and cash flow volatility should be monitored. The technical analysis indicates a neutral market sentiment, with no strong momentum in either direction.

Tauns Laboratories, Inc. Business Overview & Revenue Model

Company Description

TAUNS Laboratories, Inc. develops and manufactures vitro diagnostic drugs & measuring instruments. It also provides import and export of industrial measuring instruments, medical, physical, chemical and measuring instruments. The company was founded in April 1987 and is headquartered in Izunokuni, Japan.

How the Company Makes Money

Tauns Laboratories, Inc. generates revenue primarily through the sale of its diagnostic products to healthcare providers, hospitals, and laboratories. The company's revenue streams include direct sales of in vitro diagnostic reagents and rapid testing kits, as well as potential licensing agreements and collaborations with other biotechnology firms. Additionally, Tauns Laboratories may engage in research and development partnerships to enhance its product offerings, which can also contribute to its earnings.

Tauns Laboratories, Inc. Financial Statement Overview

Summary

Tauns Laboratories, Inc. shows strong financial health with consistent revenue growth and profitability. The balance sheet is stable, though rising debt levels warrant attention. Cash flow improvements are promising, but historical volatility should be monitored.

Income Statement

Tauns Laboratories, Inc. has demonstrated strong revenue growth with a 5.79% increase in the latest period. The company maintains robust profitability metrics with a high gross profit margin and net profit margin. EBIT and EBITDA margins are also strong, indicating efficient operations. However, the slight decline in gross profit from the previous year suggests potential cost pressures.

Balance Sheet

The balance sheet reflects a solid equity position with a debt-to-equity ratio that remains manageable. The return on equity is impressive, indicating effective use of shareholder funds. However, the increase in total debt over the years could pose a risk if not managed carefully.

Cash Flow

The cash flow statement shows a significant improvement in free cash flow growth, although the previous year's negative operating cash flow is a concern. The operating cash flow to net income ratio indicates a strong cash generation capability relative to net income, but the volatility in free cash flow suggests potential liquidity challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	17.61B	18.63B	18.43B	15.67B	17.46B
Gross Profit	12.69B	12.33B	12.50B	8.79B	14.29B
EBITDA	9.90B	9.02B	8.65B	5.32B	8.55B
Net Income	6.65B	6.32B	5.77B	3.03B	4.48B
Balance Sheet
Total Assets	37.64B	36.52B	29.26B	18.81B	20.88B
Cash, Cash Equivalents and Short-Term Investments	8.58B	9.27B	9.42B	1.24B	6.35B
Total Debt	13.63B	14.42B	9.54B	6.47B	4.90B
Total Liabilities	19.96B	19.10B	15.59B	10.32B	13.52B
Stockholders Equity	17.67B	17.42B	13.67B	8.49B	7.36B
Cash Flow
Free Cash Flow	0.00	2.14B	5.97B	-4.32B	8.39B
Operating Cash Flow	0.00	6.82B	9.94B	-3.16B	10.69B
Investing Cash Flow	0.00	-9.26B	-4.11B	-1.62B	-2.68B
Financing Cash Flow	0.00	2.28B	2.36B	-330.20M	-3.66B

Tauns Laboratories, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 555.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:197A, the sentiment is Positive. The current price of 555 is below the 20-day moving average (MA) of 557.50, below the 50-day MA of 565.36, and above the 200-day MA of 538.39, indicating a neutral trend. The MACD of -2.32 indicates Positive momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 27.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:197A.

Tauns Laboratories, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
197A	―	¥57.59B	8.94	―	4.84%	―	―
4516	―	¥218.83B	7.17	―	3.85%	6.83%	11.59%
4554	―	¥38.54B	12.53	7.10%	2.88%	12.06%	-51.89%
4569	―	¥73.96B	7.84	―	3.70%	9.83%	86.18%
4886	―	¥57.64B	12.11	―	2.48%	6.23%	-31.45%
4887	―	¥190.88B	207.85	―	2.94%	3.52%	-95.28%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Tauns Laboratories, Inc. Corporate Events

Tauns Laboratories Reports Modest Growth and Positive Outlook

Tauns Laboratories, Inc. reported its financial results for the fiscal year ending June 30, 2025, showing a modest increase in net sales and operating income compared to the previous year. The company experienced a notable rise in net income by 9.4%, reflecting strong operational performance. The financial position of the company improved with an increase in total assets and net assets, while cash flows from operating activities decreased. The company announced a slight increase in annual dividends per share, maintaining a stable payout ratio. Looking ahead, Tauns Laboratories forecasts a significant rise in net income for the fiscal year ending June 30, 2026, indicating positive expectations for future growth.